Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease

Pediatric Nephrology

Volumn 21, Issue 8, 2006, Pages 1144-1152

  Warady, Bradley A ^a   Arar, Mazen Y ^b   Lerner, Gary ^c   Nakanishi, Arline M ^d   Stehman Breen, Catherine ^d  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d AMGEN INC   (United States)

Author keywords

Anemia; Chronic kidney disease; Darbepoetin alfa; Dialysis; End stage renal disease; Pediatrics

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADOLESCENT; ADULT; ALOPECIA; ANEMIA; ARTICLE; CHILD; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FEVER; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; INJECTION SITE PAIN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIAPISM; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEPSIS; THROMBOSIS; UPPER RESPIRATORY TRACT INFECTION;

ANEMIA; CHILD; CHRONIC DISEASE; ERYTHROPOIETIN; FEMALE; HEMATINICS; HUMANS; KIDNEY DISEASES; MALE;

EID: 33746148160     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-006-0071-0     Document Type: Article

References (48)

1. Caro J, Brown S, Miller O, Murray T, Erslev AJ (1979) Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med 93:449-458
2. Astor BC, Muntner P, Levin A, Eustace JA, Coresh J (2002) Association of kidney function with anemia: The Third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 162:1401-1408
3. McClellan W, Aronoff SL, Bolton WK, Hood S, Lorber DL, Tang KL, Tse TF, Wasserman B, Leiserowitz M (2004) The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 20:1501-1510
4. Klang B, Bjorvell H, Clyne N (1996) Quality of life in predialytic uremic patients. Qual Life Res 5:109-116
5. Gerson A, Hwang W, Fiorenza J, Barth K, Kaskel F, Weiss L, Zelikovsky N, Fivush B, Furth S (2004) Anemia and health-related quality of life in adolescents with chronic kidney disease. Am J Kidney Dis 44:1017-1023
6. Mitsnefes MM, Daniels SR, Schwartz SM, Meyer RA, Khoury P, Strife CF (2000) Severe left ventricular hypertrophy in pediatric dialysis: prevalence and predictors. Pediatr Nephrol 14:898-902
7. Chavers BM, Herzog CA (2004) The spectrum of cardiovascular disease in children with predialysis chronic kidney disease. Adv Chronic Kidney Dis 11:319-327
8. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR (1999) Normalizing hematocrit in dialysis patients improves brain function. Am J Kidney Dis 33:1122-1130
9. Pattaragarn A, Warady BA, Sabath RJ (2004) Exercise capacity in pediatric patients with end-stage renal disease. Perit Dial Int 24:274-280
10. Sietsema KE, Hiatt WR, Esler A, Adler S, Amato A, Brass EP (2002) Clinical and demographic predictors of exercise capacity in end-stage renal disease. Am J Kidney Dis 39:76-85
11. Xia H, Ebben J, Ma JZ, Collins AJ (1999) Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10:1309-1316
12. Ma JZ, Ebben J, Xia H, Collins AJ (1999) Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619
13. Warady BA, Ho M (2003) Morbidity and mortality in children with anemia at initiation of dialysis. Pediatr Nephrol 18:1055-1062
14. Portoles J (2001) The beneficial effects of intervention in early renal disease. Nephrol Dial Transplant 16(Suppl 2):12-15
15. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F (2000) Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 11:335-342
16. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ (2000) Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol Dial Transplant 15:1425-1430
17. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR, Benz RL (1995) Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25:548-554
18. Becker BN, Becker YT, Leverson GE, Heisey DM (2002) Erythropoietin therapy may retard progression in chronic renal transplant dysfunction. Nephrol Dial Transplant 17:1667-1673
19. Fink J, Blahut S, Reddy M, Light P (2001) Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 37:348-355
20. Obrador GT, Ruthazer R, Arora P, Kausz AT, Pereira BJ (1999) Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States. J Am Soc Nephrol 10:1793-1800
21. NAPRTCS (2005) NAPRTCS 2005 Annual Report. Available at http://spitfire.emmes.com/study/ped/index.htm. Accessed Sept 1, 2005.
22. USRDS (2004) U.S. Renal Data System, USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2004. Accessed June 20, 2005.
23. NKF-K/DOQI (2001) IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 37:S182-S238
24. Frankenfield DL, Neu AM, Warady BA, Fivush BA, Johnson CA, Brem AS (2003) Anemia in pediatric hemodialysis patients: Results from the 2001 ESRD Clinical Performance Measures Project. Kidney Int 64:1120-1124
25. Fadrowski JJ, Furth SL, Fivush BA (2004) Anemia in pediatric dialysis patients in end-stage renal disease network 5. Pediatr Nephrol 19:1029-1034
26. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J (2003) Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21:414-421
27. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA (2003) Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 31:290-299
28. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J (1999) Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10:2392-2395
29. Lerner G, Kale AS, Warady BA, Jabs K, Bunchman TE, Heatherington A, Olson K, Messer-Mann L, Maroni BJ (2002) Pharmacokinetics of darbepoetin alfa in pediatric patients with chronic kidney disease. Pediatr Nephrol 17:933-937
30. Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S (2004) Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 24:453-460
31. Suranyi MG, Lindberg JS, Navarro J, Elias C, Brenner RM, Walker R (2003) Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 23:106-111
32. Ling B, Walczyk M, Agarwal A, Carroll W, Liu W, Brenner R (2005) Darbepoetin alfa administered once monthly maintains hemoglobin concentrations in patients with chronic kidney disease. Clin Nephrol 63:327-334
33. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ (2004) Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 19:898-903
34. Van Damme-Lombaerts R, Herman J (1999) Erythropoietin treatment in children with renal failure. Pediatr Nephrol 13:148-152
35. De Palo T, Giordano M, Palumbo F, Bellantuono R, Messina G, Colella V, Caringella AD (2004) Clinical experience with darbepoietin alfa (NESP) in children undergoing hemodialysis. Pediatr Nephrol 19:337-340
36. Geary DF, Keating LE, Vigneux A, Stephens D, Hebert D, Harvey EA (2005) Darbepoetin alfa (Aranesp) in children with chronic renal failure. Kidney Int 68:1759-1765
37. Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Baker NF, Gray SJ (2002) Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 62:2167-2175
38. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ (2002) Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40:110-118
39. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1-S266
40. (1987) Report of the Second Task Force on Blood Pressure Control in Children-1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland. Pediatrics 79:1-25
41. (1996) Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: A working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics 98:649-658
42. Warady BA, Alexander SR, Watkins S, Kohaut E, Harmon WE (1999) Optimal care of the pediatric end-stage renal disease patient on dialysis. Am J Kidney Dis 33:567-583
43. Yorgin PD, Belson A, Al-Uzri AY, Alexander SR (2001) The clinical efficacy of higher hematocrit levels in children with chronic renal insufficiency and those undergoing dialysis. Semin Nephrol 21:451-462
44. Seikaly MG, Ho PL, Emmett L, Fine RN, Tejani A (2003) Chronic renal insufficiency in children: The 2001 Annual Report of the NAPRTCS. Pediatr Nephrol 18:796-804
45. Schroder CH (2003) The management of anemia in pediatric peritoneal dialysis patients. Guidelines by an ad hoc European committee. Pediatr Nephrol 18:805-809
46. Warady BA, Kausz A, Lerner G, Brewer ED, Chadha V, Brugnara C, Dahl NV, Watkins SL (2004) Iron therapy in the pediatric hemodialysis population. Pediatr Nephrol 19:655-661
47. Warady BA, Zobrist RH, Wu J, Finan E (2005) Sodium ferric gluconate complex therapy in anemic children on hemodialysis. Pediatr Nephrol 20:1320-1327
48. Cervelli MJ, Gray N, McDonald S, Gentgall MG, Disney AP (2005) Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients. Nephrology (Carlton) 10:129-135